TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00878111

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NGR-hTNF
Description: First cohort: iv q3W 60 mcg/sqm over 120 min\*~Second cohort: iv q3W 80 mcg/sqm over 120 min\*~Third cohort: iv q3W 100 mcg/sqm over 120 min\*~Fourth cohort: iv q3W 125 mcg/sqm over 120 min\*~Fifth cohort: iv q3W 150 mcg/sqm over 120 min\*~Sixth cohort: iv q3W 175 mcg/sqm over 120 min\*~Seventh cohort: iv q3W 200 mcg/sqm over 120 min\*~Eighth cohort: iv q3W 225 mcg/sqm over 120 min\*~Ninth cohort: iv q3w 250 mcg/sqm over 120 min\*~Tenth cohort: iv q3w 275 mcg/sqm over 120 min\*~Eleventh cohort: iv q3w 300 mcg/sqm over 120 min\*~Twelfth cohort: iv q3w 325 mcg/sqm over 120 min\*~\* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period.
Study: NCT02293447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine per-embolization
Description: 10mL of 1% lidocaine will be mixed with the embolization particles. Lidocaine will therefore be injected during the embolization.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine post-embolization
Description: 10mL of 1% lidocaine will be injected in both uterine arteries after the embolization endpoint is achieved.
Study: NCT04118270

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Afib 2gether TM Mobile Application
Description: The Afib 2gether mobile app determines a patient's stroke risk through a series of questions that the patient will answer in the app.
Study: NCT04489251

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein Elisa analysis, microRNA analysis, whole exome sequencing
Description: ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing.

Intervention type: DIAGNOSTIC_TEST
Intervention: Protein Elisa analysis, microRNA analysis, whole exome sequencing
Description: ELISA Testing Procedure: The circulating levels of BMP 2, 4, 6, 7, 9 and 10, together with activin A and TGF-β as well as CHIP will be measured using streptavidin ELISA assays.~Micro-RNA analysis: From 100µL of plasma, we will prepare small RNA libraries using TruSeq Small RNA Sample Preparation kit (Illumina Inc).~TGF-B mutation evaluation: Blood from subjects with PH will also be analyzed for known genetic mutations in TGF-B pathway using whole exome sequencing.
Study: NCT02546765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen & IV propofol
Description: use of IV tylenol and IV propofol for pain and sedation (respectively)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV acetaminophen & IV dexmedetomidine
Description: use of IV tylenol and IV dexmedetomidine for pain and sedation (respectively)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV propofol & placebo
Description: use of IV propofol for sedation and morphine, the drug of choice for cardiac pain

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV dexmedetomidine & placebo
Description: use of IV dexmedetomidine for sedation and morphine, the drug of choice for cardiac pain
Study: NCT01660321

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: spinosad
Description: A sufficient amount of Natroba Topical Suspension was applied to completely cover the scalp, worked out to the ends of the hair, and left in place for 10 minutes (±30 seconds), followed by a complete rinse and shampoo.
Study: NCT00036751

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: Given orally

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT02698748

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chloroquine
Description: Chloroquine sulphate (Meriquine®; 250mg; 150 mg of chloroquine base; Baroda, India) will be administered at a total dose of 25 mg/kg (expressed as mg of CQ base per kg body weight, once daily during 3 consecutive days, following the schedule 10mg/kg Day 1; 10mg/kg day 2 and 5 mg/kg day 3).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Placebo pills will be standard placebo capsules filled with powder contents with no pharmaceutical activity. They will not be identical to the chloroquine tablets, so the study will not be double blind, but rather single blinded. Placebo tablets will be manufactured by the pharmaceutical department of the Hospital Clínic, in Barcelona, Spain
Study: NCT02669966

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kidney transplantation
Description: Once the donor and recipient candidates have met inclusion criteria and cleared study-specific as well as standard of care screening, they will proceed to live-donor kidney transplantation and subsequent post-transplant monitoring
Study: NCT02034630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Busulfan
Description: First dose: busulfan (120 mg/m2 ivs once daily) (if age\<1 yr: 80 mg/ m2) Second to forth dose: according to the daily pharmacokinetic study
Study: NCT01377064

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Physical Activity Group
Description: 9 months of home based physical activity meeting HHS recommendations for physical activity for all americans

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Care Group
Description: No intervention, the group will be followed under their standard medical care.
Study: NCT04919291

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Topoguided LASIK
Description: Topoguided ablation profile on dominant eye

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Wavefront optimized LASIK
Description: Wavefront optimized ablation profile on non-dominant eye
Study: NCT04095728

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Brain Octane Oil
Description: Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will complete a 7-day dose escalation period, and then consume 2 servings of the study product (1 serving = 1 tablespoon) for 21 days.
Study: NCT02580851

Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic test - cardiac magnetic resonance imaging

Intervention type: OTHER
Group type: OTHER
Intervention: diagnostic test - coronary angiography
Study: NCT02109562

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBP-7000
Description: RBP-7000 90 mg and 120 mg were a mixture of the ATRIGEL Delivery System and 90 mg and 120 mg risperidone, respectively. The ATRIGEL Delivery System allows for sustained-release of risperidone in a controlled manner. Subcutaneous RBP-7000 injections on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous injection of placebo using the ATRIGEL Delivery System on Days 1 and 29 in the lower quadrant of the abdomen rotating right and left on day 1 and 29.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Risperidone
Description: Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Risperidone
Description: Oral risperidone 0.25 mg tablets daily for the first two days of the screening period. The two 0.25 mg tablets confirmed whether study participants had any negative reaction to risperidone prior to receiving a long-acting injection of risperidone (RBP-7000).
Study: NCT04425720

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LifeSignals Biosensor 1AX*
Description: Shared-clinical decisions will be made based on the monitored data and patient diary. Two devices will be used to monitor data, LifeSignals Biosensor 1AX\* and a pulse oximeter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: This group will be treated based on standard of care at our institution.
Study: NCT00947700

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assessment, Monitoring & Intervention
Description: Assessment and monitoring at 6, 12, 18 and 24 months; Parent delivered intervention provided between 6 and 12 months.
Study: NCT01248286

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Whole grain rice
Description: Whole grain rice arm (treatment arm): Subjects will be provided a supply of whole grain rice and will be asked to prepare rice items in their meal with the provided whole grain rice while participating in the study

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Refined grain rice
Description: Refined grain rice arm (control arm): Subjects will be provided a supply of refined grain rice and will be asked to prepare rice items in their meal with the provided refined grain rice while participating in the study
Study: NCT03688399

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IOL implantation experimental
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> intermediate \> near

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: IOL implantation comparator
Description: Implantation of trifocal IOL POD F GF consisting of light distribution order: far \> near \> intermediate
Study: NCT00288249

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 16 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 12 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 30-minute i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sagopilone (BAY86-5302, ZK 219477)
Description: 22 mg/m2, 3-hour i.v. infusion, 1 cycle every 3 weeks. Planned number of cycles : 2-6.
Study: NCT00488111

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ringer's Lactate
Description: Ringer's Lactate was used 15min before operation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 6% Starch
Description: 6% Starch was used 15min before operation
Study: NCT03392792

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: tissue plasminogen activator
Description: role of tissue plasminogen activator in patient with acute ischemic stroke having selective criteria for rTPA

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thrombectomy
Description: role of thrombectomy in patient with acute ischemic stroke
Study: NCT02958007

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Peer Education on Exercise for Recovery
Description: A 24-week group-based peer coaching intervention delivered by a VA Peer Specialist, to promote participation in a supervised fitness training program and general physical activity

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced supervised fitness training
Description: A 24-week intervention to promote participation in a supervised fitness training program and general physical activity, which includes individual support from non-peer staff
Study: NCT02321930

Intervention type: DRUG
Group type: OTHER
Intervention: tofacitinib 5mg po bid
Study: NCT02483377

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT01164566

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endoscopic procedure

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: questionnaire administration
Description: Ancillary studies
Study: NCT00971763

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisolone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study: NCT00664495

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Diet Weight Loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Weight Loss

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Exercise Without Weight Loss
Study: NCT00199602

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarine - low molecular heparin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarine - low molecular heparin
Study: NCT02441413

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: High Resolution Computed Tomography scans
Description: A HRCT scan at Functional Residual Capacity (FRC) and Total Lung Capacity (TLC) will be taken on visit 1, visit 2, visit 3, visit 4 and visit 5.~An Upper Airway (UA) scan will be taken on visit 1.
Study: NCT04475640

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood sample

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genetic Testing
Description: Undergo genetic testing
Study: NCT00470054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given PO
Study: NCT00798135

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: itraconazole
Description: oral itraconazole 200mg a day until disease progression or unacceptable toxicities.
Study: NCT01129921

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Lumbar Decompression
Description: Fluoroscopic percutaneous lumbar decompression of the central spinal canal

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham lumbar decompression
Description: Sham fluoroscopic percutaneous lumbar decompression with no bone or tissue removal.
Study: NCT02876120

Intervention type: OTHER
Group type: OTHER
Intervention: Implementation
Description: Multifaceted implementation strategy to implement evidence based international osteoarthritis treatment recommendations among GPs and PTs in private practice, template for PT discharge reports to GP, patient osteoarthritis education programs, and facilitate multidisciplinary collaboration between the PTs and GPs.
Study: NCT01401842

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar ext. high intensity progressive resistance exercise
Description: 1 active set of 1 exercise, 1x/week, 11 weeks

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low intensity core stabilization exercise
Description: 1 set of 5 exercises, 1x/week, 11 weeks
Study: NCT04248309

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intramuscular progesterone 20-40mg from D3 until pregnancy test
Description: serum progesterone \<7.24ug/L, followed by randomized A1: plus additional treatment（intramuscular progesterone 20-40mg from D3 ）
Study: NCT02000076

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Partial sleep deprivation allowing 3 h sleep at night
Description: Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Full sleep
Description: Participants sleep at home while monitored with ambulatory polysomnography. For the full sleep condition, they are instructed to go to bed and to get up at the usual times that they would normally do that. For the sleep deprivation condition, they are instructed to go to bed 3 hours before the time when they would usually get up, and then to get up at that time.
Study: NCT04191187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 30mg/m\^2/day will be administered over 30-60 minutes intravenous infusion on Days -6 through -2 for a total dose of 150 mg/m\^2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Melphalan 70 mg/m\^2 over 45 minutes will be administered Day -6. Melphalan dose will be calculated based on Actual Body Weight.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total Body Irradiation
Description: Total Body Irradiation (TBI) will be delivered at a dose of 200 centigray units (cGy)
Study: NCT03592966

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Wild Blueberry Powder
Description: Freeze-dried whole fruit blueberry drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Freeze-dried placebo powder
Study: NCT03372928

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Standard EAA
Description: EAA provided relative to body mass at a standard dose (0.10 g/kg) during energy deprivation

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High EAA
Description: EAA provided relative to body mass at a high dose (0.30 g/kg) during energy deprivation
Study: NCT02589496

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pembrolizumab
Description: 200 mg every 3 weeks
Study: NCT05065931

Intervention type: OTHER
Intervention: Auxiliary diagnostic system by AI-CDSS
Description: Helping clinicians to make diagnoses by using CDSS based-on AI
Study: NCT04076254

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Albumins
Description: albumin 5%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluid
Description: Ringer Lactate
Study: NCT04375787

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Atorvastatin
Description: Patients received 80 mg atorvastatin before elective coronary angiography

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atorvastatin
Description: Patients received 80 mg atorvastatin before elective coronary angiography
Study: NCT01383980

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Continuous Tube Feedings
Description: Tube feeds continued up until elective surgery.
Study: NCT03289949

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybine
Description: Oral dose of psilocybine.

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybine
Description: Oral dose of psilocybine.

Intervention type: DRUG
Group type: OTHER
Intervention: Psilocybine
Description: Oral dose of psilocybine.

Intervention type: DRUG
Group type: OTHER
Intervention: Ketanserin
Description: Oral dose of ketanserin.

Intervention type: DRUG
Group type: OTHER
Intervention: Ketanserin
Description: Oral dose of ketanserin.
Study: NCT02413840

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Baduanjin qigong
Study: NCT03311321

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2 (menaquinone-7; 360-mcg/d)
Description: four 90-mcg vitamin K2 (menaquinone-7) softgel capsules per day for 8 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo-Control
Description: four placebo softgel capsules per day for 8 weeks containing no vitamin K2 (menaquinone-7)
Study: NCT04540549

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Jogging or cycling ≥5 days/week, 30-60 min/d
Study: NCT01932242

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: Monoclonal Antibody

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ETI-204
Description: Monoclonal Antibody

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for ETI-204
Study: NCT04063241

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Literacy-Informed Discharge Instructions
Description: Web-based disease-specific instruction sheets that will be printed with the research team's help. Providers will reference these instructions as they perform discharge counseling and will give parents a copy of the instructions to refer to at home.

Intervention type: OTHER
Group type: OTHER
Intervention: Provider Training
Description: 20-minute long provider training session, including information about health literacy, advanced counseling strategies, results of prior studies, and pre-implementation data.
Study: NCT03329196

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT-6548
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Darbepoetin alfa
Description: Subcutaneous
Study: NCT01992120

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Debriefing of high-fidelity sepsis simulation scenarios
Description: Educational intervention

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo: Debriefing of high-fidelity non-sepsis simulation scenarios
Study: NCT02525393

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tDCS
Description: Stroke rehabilitation performed with the aid of a transcranial electrical stimulation device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Stroke rehabilitation performed with the aid of a repetitive transcranial magnetic stimulation device.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Stroke sham stimulation performed with the aid of a transcranial electrical stimulation device.